Rather than accusing Russia of using Novichok against its citizens, maybe we should pay more attention to real drug developments by Russia which may assist us in the present pandemic crisis. But that's asking too much, it seems...Russian drug – five times lower death rate in severe Covid-19 cases
By Newsdesk -2020-09-140
https://www.almasdarnews.com/article/ru ... -19-cases/
The Russian drug “Surfactant-BL” was developed for the treatment of severe lung lesions and has helped to reduce the death rate in severe cases of COVID-19 from 80 to 14.3 percent.
A new Russian drug for the treatment of severe lung lesions has shown great promise in preliminary clinical trials in COVID-19 patients. The new drug called “Surfactant-BL” protects the alveoli from collapsing and thus ensures a significantly better oxygen supply to the whole body even if the lungs are badly damaged.
The so-called surfactant itself is a liquid that flushes the alveoli from the inside out. It is explained that the abbreviation “BL” in the name of the drug stands for ” бычьи лёгкие ” ( bytschji ljogkije , English: “bull’s lung”) – because the decisive active ingredient is obtained from the lungs of cattle.
While further studies and tests are required for the newly developed drug, the Ministry of Health is planning to include it for the treatment of patients with Covid-19.
On September 8, the Russian Ministry of Health also announced that the first batch of the Russian vaccine “Sputnik V” for the prevention of COVID-19 had been put into medical circulation. The country has also signed agreements with various countries to produce the vaccine.
Discussion of current events
Besides having an efficient vaccine, Russia is now supplying an efficient anti-viral. Because it is Russian I'm sure it will not be used either in Europe or in the US. Smart move, indeed...Cheaper Than Remdesivir: Russia to Supply Anti-COVID Avifavir to 17 Countries
by Aleksandra Serebriakova
https://sputniknews.com/russia/20200924 ... countries/
In late May, Russia registered the world’s first anti-COVID-19 drug, based on favipiravir, an antiviral medication. The medicine has been extensively used in Russian clinics to treat coronavirus disease since June, and has since been obtained by hospitals in Belarus, Kazakhstan, Bolivia and a number of other countries.
The Russian Direct Investment Fund (RDIF), the investor which funded the development of the world’s first vaccine against coronavirus, and Moscow-based ChemRar Group have agreed to supply the anti-COVID drug Avifavir to 17 countries.
Avifavir, the world’s first favipiravir-based drug to be approved for the treatment of COVID-19, will now be delivered to Saudi Arabia, Brazil, Bulgaria, Columbia, Serbia, Argentina, Chile, Colombia, Ecuador, El Salvador, Honduras, Kuwait, Panama, Paraguay, Serbia, Slovakia, South Africa, the UAE and Uruguay.
After being first registered in Russia on 29 May 2020, it has already been used for COVID-19 treatment in more than 70 Russian regions and subsequently purchased by Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan.
The efficacy of favipiravir against COVID-19 has been confirmed by Japan’s Fujifilm Holdings Corp, several months after Avifavir trials in Russia.
RDIF notes that in comparison to other Russian manufacturers of favipiravir, Avifavir has proven to be more effective when treating more than 400 patients, who fell ill with the coronavirus disease since April. The drug has now been approved by European, Middle Eastern and Asian regulators, becoming Russia’s number one anti-coronavirus medication for export.
According to RDIF, it is also a much cheaper option in comparison to Remdesivir, a favipiravir-based drug produced in the United States.
“When we registered the first anti-coronavirus drug in the world based on favipiravir, there was a lot of scepticism as people were wondering how we could register it when Japan had not registered it yet,” says Kirill Dmitriev, CEO of the Russian Direct Investment Fund. “Now five months after our clinical trials, we see that Japan has confirmed the clinical efficacy of favipiravir.”
The RDIF CEO stresses that apart from clinical trials which were conducted at 35 medical centres in Russia, Avifavir’s efficiency has also been tested by 940 patients in observational post-registration studies, which made it “the largest clinical trial of a favipiravir-based drug against coronavirus in the world”.
“Based on our extensive clinical trials and the research in Japan confirming favipiravir’s efficacy against coronavirus we believe that Avifavir and other favipiravir-based products will be the leading antiviral medicines against COVID-19 in the world,” Dmitriev adds. “In addition to proven efficacy and safety Avifavir is also three to four times cheaper than Remdesivir.”
Trials Confirm Avifavir’s Efficiency
According to the results of post-registration clinical trials, those patients taking Avifavir recovered more quickly from COVID-19 symptoms, as in 30% of cases the virus was eliminated at an early stage, while the level of oxygen saturation in the patient’s blood was also restored to normal two times more quickly than when traditional therapy was applied. No adverse effects from the drug’s use have been reported. Meanwhile, the third phase of clinical trials of the Japanese favipiravir-based drug Avigan also showed a shorter time of recovery among patients with non-severe pneumonia, according to the results published on 23 September.
RDIF, Russia's sovereign wealth fund, has also been involved in the development of the world’s first anti-coronavirus vaccine, dubbed Sputnik V, which was registered in Russia on 11 August. The country has now received a request for 1 billion doses of the vaccine from at least 20 countries, including the UAE, Saudi Arabia, Indonesia, Philippines, Mexico, Brazil and India.